Bristol Myers Squibb (BMY) News Today
BMY fell 1.13% in the 10 minutes after this headline crossed at 09:33:11 ET on Monday, Oct 12:
Bristol-Myers' cancer therapy achieves primary endpoint in late-stage study, while lung disease drug demonstrates efficacy in trial.
Price 60.53 two minutes before the headline, 59.85 10 minutes after it.
Latest headline on this page:
1 headline on Bristol Myers Squibb appeared in our news feed in the last 7 days with a measured price reaction attached. 1 of them moved the underlying at least 0.35% in the minutes after the headline crossed. The largest measured reaction was -1.13% over 10 minutes on BMY, after the headline at Oct 12, 09:33:11 ET.
What moved BMY — last 7 days
| Time | Headline | 1 min | Reaction |
|---|---|---|---|
| Oct 12, 09:33:11 ET | Bristol-Myers' cancer therapy achieves primary endpoint in late-stage study, while lung disease drug demonstrates efficacy in trial. | -0.03% | -1.13% · 10m |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Reaction pending means the measuring window for that headline is still open. Not attributed means the headline does not name the company the move was measured on, so we hold the number back. Times are New York ET. Headlines appear here 1 minute after they cross the live tape.